---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-006773"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:28:14.667861+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ensysce raises $4.7M via warrant exercise, issues new warrants at $1.06

## Summary
- Gross proceeds ~$4.7M from cash exercise of 3,601,752 existing warrants at reduced price $1.31 per share.
- Issues unregistered Series A/B warrants for 7,203,504 shares at $1.06; Series A expire 18 months, Series B May 2028.
- Net proceeds for Phase 3 prep of PF614, debt repayment (Oct/Nov 2023), and general corporate.
- Placement agent H.C. Wainwright gets $200k fee and 252,123 warrants at $1.6375.
- Waiver from Oct 2023 SPA requires full note repayment with premium post-closing.

## SEC filing metadata
- accession: 0001493152-24-006773
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/0001493152-24-006773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-006773
- JSON: https://secwatch.observer/filing/0001493152-24-006773.json
- Plain text: https://secwatch.observer/filing/0001493152-24-006773.txt

## Key facts
- Material Agreements
  Ensysce Biosciences, Inc. entered into Inducement Letter with certain holders valued at approximately $4.7 million (effective 2024-02-12).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain holders
  - Value: approximately $4.7 million
  - Effective: 2024-02-12
  source text: On February 12, 2024, Ensysce Biosciences, Inc., a Delaware corporation (the “ Company ”), entered into an inducement offer letter agreement (the “ Inducement Letter ”) with certain holders (the “ Holders ”) of certain of its existing warrants to purchase up to an aggregate of 3,601,752 shares of the Company’s common stock, $0.0001 par value (the “ Common Stock ”), issued to the Holders on May 12, 2023 and having an exercise price of $3.637 per share (the “ Existing Warrants ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315224006773/0001493152-24-006773-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.